Fig. 6

Fedratinib’s impact on the viability and proliferation of LGG cells. A The GSEA of biological pathways indicated the PCD pathway, pyroptosis pathway, apoptosis pathway, and RIPK1 mediated regulated necrosis pathway in the Risk-H group. B The GSEA of signaling cascades indicated JAK-STAT signaling pathway, natural killer cell mediated cytotoxicity pathway, leukocyte transendothelial migration pathway, and antigen processing and presentation in the Risk-H group. C The Venn plot shows the intersection of the four drug screening results, with the intersection showing three drugs fedratinib, XMD-892, and MMPX. D An CCK-8 assay was used to evaluate the viability of SW1783 and SW1088 cells under different concentrations of fedratinib (1, 2, 4, 6, 8, 10, and 25 μM). Cells were treated with the same drug dose for 24 and 48 hours, respectively. GraphPad Prism was used to analyze and visualize the data from the LGG cells viability assay and the IC50 of fedratinib. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 vs. control group. E Colony formation assay was performed to detect the colony formation ability of LGG cells after fedratinib treatment. F Quantitative analysis of colony formation formed by LGG cells was performed using ImageJ, followed by visualization performed using GraphPad Prism. *P < 0.05, and **P < 0.01 vs. control group